Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Levodopa therapy and malignant melanoma.

A J Sober, M M Wick

    JAMA
    |August 11, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Levodopa is unlikely to significantly contribute to the rising incidence of malignant melanoma, despite concerns. A study of 1,099 patients found only one levodopa user, suggesting its role is minimal.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Festschrift in honor of Dr. Thomas B. Fitzpatrick.

    The Journal of investigative dermatology·2010
    Same author

    Early death from clinical stage I melanoma.

    The Journal of investigative dermatology·2010
    Same author

    Factors associated with death from melanoma from 2 to 5 years following diagnosis in clinical stage I patients.

    The Journal of investigative dermatology·2010
    Same author

    The chemotherapy of malignant melanoma.

    The Journal of investigative dermatology·2010
    Same author

    MELPREDICT: a logistic regression model to estimate CDKN2A carrier probability.

    Journal of medical genetics·2005
    Same author

    Guidelines of care for primary cutaneous melanoma.

    Journal of the American Academy of Dermatology·2001

    Area of Science:

    • Oncology
    • Dermatology
    • Pharmacology

    Background:

    • Investigating the potential link between levodopa use and the development of cutaneous malignant melanoma.
    • Addressing concerns regarding levodopa's role in melanoma induction or stimulation.

    Observation:

    • A prospective study involving 1,099 patients presenting with primary melanoma was conducted.
    • Data was collected on patient history, specifically levodopa usage.

    Findings:

    • Only one patient out of 1,099 reported taking levodopa at the time of their primary melanoma diagnosis.
    • This low prevalence suggests levodopa plays an inconsequential role in melanoma development.

    Implications:

    • The findings indicate that levodopa is unlikely to be a significant factor in the observed increase in melanoma incidence.

    Related Experiment Videos

  • Further research may be warranted, but current evidence does not support a causal relationship.